79 related articles for article (PubMed ID: 18432159)
21. Hepatitis C treatment response kinetics and impact of baseline predictors.
Lindh M; Arnholm B; Eilard A; Färkkilä M; Hellstrand K; Lagging M; Langeland N; Mørch K; Nilsson S; Pedersen C; Buhl MR; Wahlberg T; Wejstål R; Westin J; Norkrans G
J Viral Hepat; 2011 Jun; 18(6):400-7. PubMed ID: 20500548
[TBL] [Abstract][Full Text] [Related]
22. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
[TBL] [Abstract][Full Text] [Related]
23. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
[TBL] [Abstract][Full Text] [Related]
24. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.
Tsubota A; Arase Y; Someya T; Suzuki Y; Suzuki F; Saitoh S; Ikeda K; Akuta N; Hosaka T; Kobayashi M; Kumada H
J Med Virol; 2005 Jan; 75(1):27-34. PubMed ID: 15543591
[TBL] [Abstract][Full Text] [Related]
25. Optimal treatment duration for patients with HCV genotype 1 infection.
Ferenci P
J Viral Hepat; 2012 Jan; 19 Suppl 1():7-13. PubMed ID: 22233408
[TBL] [Abstract][Full Text] [Related]
26. Gamma-glutamyltransferase and rapid virological response as predictors of successful treatment with experimental or standard peginterferon-alpha-2b in chronic hepatitis C non-responders.
Bergmann JF; Vrolijk JM; van der Schaar P; Vroom B; van Hoek B; van der Sluys Veer A; de Vries RA; Verhey E; Hansen BE; Brouwer JT; Janssen HL; Schalm SW; de Knegt RJ
Liver Int; 2007 Nov; 27(9):1217-25. PubMed ID: 17919233
[TBL] [Abstract][Full Text] [Related]
27. Treatment of chronic hepatitis C in southern Taiwan.
Chuang WL; Yu ML; Dai CY; Chang WY
Intervirology; 2006; 49(1-2):99-106. PubMed ID: 16166797
[TBL] [Abstract][Full Text] [Related]
28. Reducing treatment duration in patients infected with hepatitis C genotype 1: any need for further studies?
Craxì A
Antivir Ther; 2009; 14(8):1045-9. PubMed ID: 20032534
[TBL] [Abstract][Full Text] [Related]
29. Optimizing the treatment of chronic hepatitis due to hepatitis C virus genotypes 2 and 3: a review.
Tarantino G; Craxì A
Liver Int; 2009 Jan; 29 Suppl 1():31-8. PubMed ID: 19207964
[TBL] [Abstract][Full Text] [Related]
30. [Treatment optimization in chronic hepatitis C virus infection].
Fernández Rodríguez CM; Alonso López S
Gastroenterol Hepatol; 2010 Feb; 33(2):119-25. PubMed ID: 19804920
[TBL] [Abstract][Full Text] [Related]
31. Viral factors affecting the outcome of therapy for chronic hepatitis C.
Fried MW
Rev Gastroenterol Disord; 2004; 4 Suppl 1():S8-S13. PubMed ID: 15184819
[TBL] [Abstract][Full Text] [Related]
32. Expert opinion on the treatment of patients with chronic hepatitis C.
Zeuzem S; Berg T; Moeller B; Hinrichsen H; Mauss S; Wedemeyer H; Sarrazin C; Hueppe D; Zehnter E; Manns MP
J Viral Hepat; 2009 Feb; 16(2):75-90. PubMed ID: 18761607
[TBL] [Abstract][Full Text] [Related]
33. Short-term therapy for patients with hepatitis C virus genotype 2 or 3 infection.
Dalgard O; Mangia A
Drugs; 2006; 66(14):1807-15. PubMed ID: 17040112
[TBL] [Abstract][Full Text] [Related]
34. Ribavirin considerations in treatment optimization.
Dusheiko G; Nelson D; Reddy KR
Antivir Ther; 2008; 13 Suppl 1():23-30. PubMed ID: 18432160
[TBL] [Abstract][Full Text] [Related]
35. Shortened peginterferon and ribavirin treatment for chronic hepatitis C.
Hartwell D; Jones J; Baxter L; Shepherd J
Int J Technol Assess Health Care; 2012 Oct; 28(4):398-406. PubMed ID: 22995040
[TBL] [Abstract][Full Text] [Related]
36. The importance of the definition of early virological response for predicting treatment efficacy for chronic hepatitis C.
Yu ML
Hepatology; 2011 Apr; 53(4):1403; author reply 1403. PubMed ID: 21480349
[No Abstract] [Full Text] [Related]
37. Chronic hepatitis C therapy: changing the rules of duration.
Pearlman BL
Clin Gastroenterol Hepatol; 2006 Aug; 4(8):963-71. PubMed ID: 16843732
[TBL] [Abstract][Full Text] [Related]
38. Epidemiology and treatment outcomes of patients with chronic hepatitis C and genotypes 4 to 9.
Nguyen MH; Keeffe EB
Rev Gastroenterol Disord; 2004; 4 Suppl 1():S14-21. PubMed ID: 15184820
[TBL] [Abstract][Full Text] [Related]
39. A controlled study of nitazoxanide (NTZ) 3 years after treatment of hepatitis C genotype 4.
Kabil SM; Soliman MS; Youssef SM; Mounier BI
J Egypt Soc Parasitol; 2011 Aug; 41(2):251-61. PubMed ID: 21980765
[TBL] [Abstract][Full Text] [Related]
40. Analysis of the virus dynamics model reveals that early treatment of HCV infection may lead to the sustained virological response.
Gupta S; Singh R
PLoS One; 2012; 7(7):e41209. PubMed ID: 22911761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
